关于广泛实施阿尔茨海默病的基于血液的生物标志物的考虑
Michelle M Mielke1, Matthew Anderson2, J Wesson Ashford3,4
1Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
概括
基于血液的生物标志物 (BBM) 对早期阿尔茨海默症有希望.
科学领域:
- 神经学和临床诊断的神经学和临床诊断
- 生物标志物研究和开发
背景情况:
- 诊断阿尔茨海默病 (AD) 是一个挑战,导致延迟护理.
- 基于血液的生物标志物 (BBM) 提供了早期AD检测和干预的潜力.
- 在美国,BBM的广泛临床使用受到几个因素的阻碍.
研究的目的:
- 解决阻碍阿尔茨海默病临床实施的挑战.
- 为有效地将BBM纳入医疗保健提供建议.
- 促进基于证据的指导方针和多方利益相关者参与BBM使用.
主要方法:
- 召开全球首席执行官倡议对阿尔茨海默病的BBM工作组.
- 确定BBM临床整合的关键考虑因素.
- 根据专家的共识和所识别的挑战,制定建议.
主要成果:
- 主要挑战包括缺乏一致的认知评估指南,对BBM测试特征的理解有限,以及对不同人群的数据不足.
- 试验结果的伦理管理是临床实施的关键考虑因素.
- 建议强调基于证据的指导方针,专业培训,患者赋权和基于社区的研究.
结论:
- 应对当前的挑战对于阿尔茨海默病BBMs的成功临床整合至关重要.
- 多方利益相关者的参与对于开发可信的指导和教育至关重要.
- 实施建议将促进及时干预,并改善阿尔茨海默病患者的护理.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.粉样蛋白是什么 粉样蛋白生物标志物生物标志物基于血液的生物标志物临床实施 临床实施临床实践中的临床实践认知障碍是一种认知障碍.改变疾病的治疗方法.伦理学 伦理 伦理学患者的旅程 患者的旅程主要护理是一级医疗保健.这是次要的护理.更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
779
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170